Federal regulators have granted expedited approval to Eli Lilly’s new weight-loss pill, Foundayo, establishing it as the second daily oral medication for obesity and related conditions.
The drug, orforglipron, is a GLP-1 medication. It mimics a natural hormone controlling appetite and fullness, similar to widely used injectable treatments. Shipments of Foundayo are set to begin this Monday.
Eli Lilly stated insured patients could get the drug for $149 per month to $349 per month, depending on the dose. This pill joins Novo Nordisk’s oral Wegovy, which has seen over 600,000 US prescriptions since its December approval.
The FDA authorized Eli Lilly’s drug as part of a new program aimed at cutting drug approval times. The agency said it reviewed the company’s application in 50 days.
In a clinical trial of more than 3,000 adults with obesity, participants who received the highest dose of orforglipron, 36 milligrams, lost 11.2% of their body weight –- about 25 pounds on average –- over more than 16 months. That compared with a 2.1% weight loss, or less than 5 pounds, in patients who received a placebo, or dummy pill, according to the New England Journal of Medicine.
Both the Lilly and Novo Nordisk pills resulted in less weight loss than the average achieved with Lilly’s injectable Zepbound, which results in a 21% average weight loss, or Novo Nordisk’s injectable Wegovy, which averages about 15%.
Both once-daily pills promise convenience, but orforglipron is a small-molecule GLP-1 drug that can be taken without restrictions. The Wegovy pill, a peptide, must be taken with a sip of water in the morning on an empty stomach, with a 30-minute wait before eating or drinking.
Users of orforglipron also saw improvements in waist circumference, blood pressure, triglyceride levels and cholesterol levels, the study found.
Side effects, mostly gastrointestinal issues, led between 5% and 10% of participants in the orforglipron study to discontinue treatment, compared with nearly 3% in the placebo group.
About 1 in 8 people in the U.S. have used injectable GLP-1 drugs, according to a survey from KFF, a nonprofit health policy research group. But many more have trouble affording the costly shots.
The pill from Indianapolis-based Lilly will be included in a Trump administration deal to lower prices on GLP-1 drugs.
